Regulating the Nrf2/HO-1 pathway may be a way to treat IBD with Sishen Pills (Zhang et al., 2021b), involving their active metabolites such as myristicin (Ismail Abo El-Fadl and Mohamed, 2022), linalool (Tekeli et al., 2018), rutaecarpine (Zhang et al., 2020b) and schisandrin B (Zhang et al., 2021a). The gene discussed is HMOX1; the disease is irritable bowel syndrome.